Government Documents, Bills, Conferences, and Working Groups

Federal

AGS Excerpt from the TBDWG September 12, 2019 meeting summary
Alpha-Gal Subcommittee

Together, the three Co-Chairs of the Alpha-Gal Subcommittee presented the subcommittee’s work. Leigh Ann first introduced herself, the other two Co-Chairs, and other members of the subcommittee and highlighted their expertise related to alpha-gal syndrome (AGS) and tick-borne diseases in general.

Report Goals

Leigh Ann noted that the overall objective of the subcommittee is its final report to the Working Group, and that the subcommittee has aligned its goals with the Working Group’s goals. The subcommittee, Leigh Ann noted, is taking an overarching approach to look at a number of important topics (for example, cause[s], treatment, and prevention of AGS). To achieve these goals, the subcommittee has sought input from subject matter experts, patients, and cross-functional stakeholders to enhance understanding of AGS; and they have identified areas of additional research need. Leigh Ann noted that the ultimate goal is to advance human protection and reduce human suffering.

Background and Identified Needs

Subcommittee Co-Chair Scott Palmer Commins, BS, MD, PhD, Associate Professor of Medicine & Pediatrics, University of North Carolina; Member, UNC Food Allergy Initiative, Thurston Research Center, then explained the characteristics of AGS, provided brief background information, and explained the special needs identified by the subcommittee thus far.

Distinct factors of AGS
  • AGS is an allergic reaction to mammalian meat; some people may also be allergic to dairy, cheese, and gelatin.
  • AGS is associated primarily with bites from the lone star tick.
  • AGS is not currently recognized/reportable as a tick-borne disease by the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC).
  • Symptoms of AGS may vary in individual pediatric and adult patients.
  • AGS may significantly change a patient’s lifestyle, and co-factors (for example physical activity, alcohol, and stress) may affect individual allergic reactions and exposure as mammalian products are ubiquitous.
  • AGS does not appear to be caused by a pathogen.
  • Factors of AGS similar to those of other tick-borne diseases
  • AGS drastically affects the lives of the patients and their families and caregivers.
  • Currently there are no FDA-approved therapeutic products for AGS; treatment plans are generally “off-label,” which may affect payer coverage, and/or part of clinical protocols.
  • Brief background and special needs
  • AGS is an allergy that develops in response to tick bite(s); however, currently there is no evidence proving that it is an infectious disease or caused by a pathogen.
  • Accumulating data suggest there is an increase in AGS incidence and an expanding geographic risk.
  • Establishing an AGS diagnosis code and diagnostic marker(s) would further help the understanding of AGS prevalence.
  • Including human tick-bite data in epidemiological investigations and linking them to clinical data would help overcome the limitations of current alpha-gal surveillance and risk assessment.
  • Major Challenges and Issues
  • Scott further explained that the subcommittee has identified the following major challenges and issues.
More information is needed to develop educational materials and programs and to improve patient outcome, including the following.
  • Accurate diagnostic data on the scope and incidence of AGS
  • Knowledge of how to identify individuals pre-disposed to AGS
  • Treatment guidelines/plans
  • Validated resources related to foods and other products containing alpha-gal
Next Steps

Co-Chair Angel M. Davey, PhD, Program Manager, Tick-Borne Disease Research Program, Congressionally Directed Medical Research Programs, U.S. Department of Defense, noted that, moving forward, the subcommittee would continue seeking expert input, begin putting all information together, and start working on the Results section. The subcommittee, she added, was aiming to complete their report before the January 2020 deadline.

DISCLAIMER:

DISCLAIMER:

 All the information on alphagalinformation.org (“here” “this site”) is provided in good faith, but we, the creators and authors of the Alpha-gal Information website (“we” “us” or “our”) offer no representation or warranty, explicit or  implied, of the accuracy, adequacy, validity, reliability, availability, or completeness of any information on this site. Under no circumstances should we have any liability for any loss or damage incurred by you as a result of relying on information provided here. The user assumes all risk of using information provided here.

We are not physicians or medical professionals, medical or scientific researchers, or experts of any kind. We are laymen with alpha-gal syndrome with no medical or scientific expertise. The information provided by us on alphagalinformation.org  is provided for general informational purposes only. It may contain errors and should be confirmed by a physician. Information provided here is not medical advice and is not a substitute for the advice of a physician or other medical professional. It should not be relied upon for decisions about diagnosis, treatment, diet, food choice, nutrition, or any other health or medical decisions. For advice about making medical and health-related decisions, consult a physician.  

Alphagalinformation.org may contain links to other websites, embedded information from other websites, links to apps, or other sources of information belonging to or originating with third parties. We do not investigate, monitor, or evaluate information provided by external links or embedded third party features for accuracy, adequacy, validity, reliability, availability, or completeness. We do not warrant, endorse, or guarantee the accuracy of such information. We will not be a party to or in any way responsible for monitoring any transaction between you and any third-party provider of products, services, or information. Under no circumstances should we have any liability for any loss or damage incurred by you as a result of relying on third party information provided here. The user assumes all risk of using information provided here.

No mention of any product or service on this website constitutes an endorsement. We do not endorse any products or services mentioned here. We cannot and do not guarantee that any product or services mentioned here will not harm you, anybody with alpha-gal syndrome, or any other person. We will not be a party to or in any way responsible for monitoring any transaction between you and any third-party provider of products or services. Under no circumstances should we have any liability for any loss or damage incurred by you as a result of the use of third-party products or services. The user assumes all risk of using products and services mentioned or named on alphagalinformation.org or any third party mentioned or connected to through external links or embedded features.

You have Successfully Subscribed!